Futura Medical’s H121 results provide a timely reminder of the progress achieved this year. MED3000 was approved in Europe, with the CE Mark granted in April 2021. Collaboration agreements are in place for China and the Far East, Brazil and Mexico, and the Gulf/Middle East. The US regulatory pathway has been established, with the confirmatory FM71 study now underway. The £12m equity raise in May removes a major uncertainty, providing a cash runway through to expected US OTC approval (as early as Q123). The next major event should be announcement of the first European partner(s), followed by first MED3000 launch expected during H222. Updating our model to reflect this progress generates a Futura Medical valuation of £264m, equivalent to 92p per share
30 Sep 2021
A year of delivery, with key milestones achieved
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
A year of delivery, with key milestones achieved
Futura Medical plc (FUM:LON) | 35.8 0 (-0.1%) | Mkt Cap: 108.0m
- Published:
30 Sep 2021 -
Author:
Franc Gregori | Lala Gregorek -
Pages:
9
Futura Medical’s H121 results provide a timely reminder of the progress achieved this year. MED3000 was approved in Europe, with the CE Mark granted in April 2021. Collaboration agreements are in place for China and the Far East, Brazil and Mexico, and the Gulf/Middle East. The US regulatory pathway has been established, with the confirmatory FM71 study now underway. The £12m equity raise in May removes a major uncertainty, providing a cash runway through to expected US OTC approval (as early as Q123). The next major event should be announcement of the first European partner(s), followed by first MED3000 launch expected during H222. Updating our model to reflect this progress generates a Futura Medical valuation of £264m, equivalent to 92p per share